Immunotherapy in Lung Cancer: Treatment After IO Cessation.
NCT ID: NCT04465942
Last Updated: 2021-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2020-06-26
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option
NCT04926584
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
NCT04205552
Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients
NCT04941417
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
NCT04807114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When IO is stopped, reason for cessation and further treatment will be recorded.
Secondary endpoints are survival after IO cessation, activity of first salvage therapy, disease-free survival after IO cessation in patients receiving no further treatment.
Patients will be centrally registered at the ELCWP headquarter (Institut Jules Bordet, Brussels, Belgium).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
(chemo)immunotherapy
Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage IVA/IVB and unresectable and non irradiable stage III NSCLC naïve of immunotherapy.
* Patients who receive immunotherapy (any type) monotherapy, combined immunotherapy or in combination with chemotherapy for first or second-line treatment.
* Availability for participating in the detailed follow-up of the protocol.
* Signed informed consent.
Exclusion Criteria
* Tumours for which TNM stage at time of study inclusion cannot be assessed.
* History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumor (more than 5-year disease free interval).
* Any type of immunotherapy for previous cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Lung Cancer Working Party
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thierry Berghmans, MD, PhD
Role: STUDY_CHAIR
ELCWP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
Brussels, , Belgium
Department of Pneumology CHU Charleroi
Charleroi, , Belgium
Department of Pneumology Hôpital Saint-Joseph
Gilly, , Belgium
Hôpital Ambroise Paré
Mons, , Belgium
Hôpital Mont-Godinne
Yvoir, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Thierry Berghmans, MD, PhD
Role: primary
Ionela Bold, MD
Role: primary
Benoît Colinet, MD
Role: primary
Stéphane Holbrechts, MD
Role: primary
Sebahat Ocak, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01171
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.